BUSINESS WIRE: Pivotal study on afatinib may challenge current standard first line treatment1 for lung cancer patients ...

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.LUX-Lung 3 clinical trial data selected for late-breaking oral presentationINGELHEIM, Germany --(BUSINESS WIRE)-- 17.05.2012 --Among the numerous abstracts being presented by Boehringer Ingelheim at the 48th Annual...

Pivotal study on afatinib may challenge current standard first line treatment1 for lung cancer patients with EGFR ...

INGELHEIM, Germany--(BUSINESSWIRE)-- Among the numerous abstracts being presented by Boehringer Ingelheim at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June ...

Chemo facts

Chemotherapy, despite all the fears and misgivings associated with it, remains a very relevant treatment option for cancer.

Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Non-Small Cell Lung Cancer

MENLO PARK, Calif., May 3, 2012 - Geron Corporation (GERN) today announced that the company has completed planned enrollment of its randomized Phase 2 clinical trial of imetelstat, a telomerase ...

IsoRay, Inc. Reports Third Quarter Results

IsoRay Inc. , a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced its financial results for the third